Syngene International Ltd.
SYNGENE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹390.14.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%6.6%
- ✓Low debt (D/E < 0.5)0.09x
- ✓Positive free cash flow
- ✕Revenue growth > 10%2%
- ✕Earnings growing-20%
- ✕Net margin ≥ 10%8.5%
- ✕Current ratio > 1.51.38
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.34
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 6.34.
Weaknesses
- •Low return on equity (6.6%).
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Well off its 52-week high — possible mean-reversion.
Threats
- •Earnings contracting year on year.
About Syngene International Ltd.
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engi
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.